Back to search
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small-Cell Lung
Clinicaltrials.gov:
EU CTIS:
#2024-518276-32-00
Other:
#90301900NSC2001
Interested in this trial?
Subscribe or share this trial
Trials at a glance
Status
Enrolling
Condition
Carcinoma, Non-Small-Cell Lung
Trial type
Interventional
Trial phase
Phase 2
Investigational
product
product
Concurrent Chemo/Radiation Therapy (cCRT)
Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin
Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel
Durvalumab
JNJ-90301900
Age
18+ years old
Biological sex
All
Placebo?
No
Trial start date
December 6, 2024
Trial end date
December 31, 2028
CT.gov ID
#NCT06667908
Share the trial ID with your doctor to see if trial participation is right for you. Participation depends on an independent medical assessment.
Countries:
- Australia,
- Brazil,
- China,
- France,
- Hong Kong,
- Netherlands,
- Spain,
- Turkey (Türkiye),
- United Kingdom,
- United States
Loading...
Enrolling
Amsterdam, Netherlands, 1066 CX
Enrolling
Boston, Massachusetts, United States, 02215
Enrolling
Pamplona, Spain, 31008
Enrolling
Dongguan, China, 523109
Enrolling
Atlanta, Georgia, United States, 30306
Enrolling
Pinehurst, North Carolina, United States, 28374
Enrolling
Barretos, Brazil, 14784 400
Enrolling
Villejuif, France, 94805
Enrolling
Brest, France, 29200
Enrolling
Marseille, France, 13015
Enrolling
Paris, France, 75020
Enrolling
Santiago de Compostela, Spain, 15706
Enrolling
Madrid, Spain, 28041
Enrolling
Valencia, Spain, 46026
Enrolling
Paris, France, 75248
Enrolling
Houston, Texas, United States, 77030
Enrolling
North Ryde, Australia, 2109
Enrolling
Istanbul, Turkey (Türkiye), 34899
Enrolling
New York, New York, United States, 10065
Enrolling
New York, New York, United States, 10016
Enrolling
Portland, Oregon, United States, 97239
Enrolling
Orlando, Florida, United States, 32806
Enrolling
Shatin, Hong Kong
Enrolling
Nijmegen, Netherlands, 6525 GA
Enrolling
Herston, Australia, 4029
Enrolling
Parkville, Australia, 3050
Enrolling
New Brunswick, New Jersey, United States, 08901
Enrolling
Sakarya, Turkey (Türkiye), 54100
Enrolling
Nedlands, Australia, 6009
Enrolling
São Paulo, Brazil, 05651 901
Enrolling
São Paulo, Brazil, 01308 050
Enrolling
Jinan, China, 250117
Enrolling
Guangzhou, China, 510080
Enrolling
London, United Kingdom, NW1 2BU
Enrolling
Cleveland, Ohio, United States, 44106
Enrolling
Farmington, Connecticut, United States, 06030
Enrolling
Miami, Florida, United States, 33136
Enrolling
Chapel Hill, North Carolina, United States, 27514
Enrolling
Philadelphia, Pennsylvania, United States, 19104
Enrolling
Burlington, Vermont, United States, 05401
Enrolling
New Haven, Connecticut, United States, 06519
#
More than 50 sites in this region
#
More than 10 sites in this region
#
Less than 10 sites in this region
Individual sites
Access detailed information on the trial:
Clinical trials information
© Johnson & Johnson and its affiliates 2026
